Sysmex (OTCMKTS:SSMXY) Trading Up 8.6% – Here’s Why

Sysmex Corporation ADR (OTCMKTS:SSMXY) traded up 8.6% on Monday . The company traded as high as $9.7495 and last traded at $9.7495. Approximately 422 shares traded hands during trading, a decline of 100% from the average daily volume of 245,966 shares. The stock had previously closed at $8.98.

Wall Street Analysts Forecast Growth

Separately, Citigroup downgraded shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. The firm has a fifty day moving average of $8.74 and a 200 day moving average of $9.09. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of 25.66 and a beta of 1.07.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The company had revenue of $877.92 million during the quarter, compared to analyst estimates of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, sell-side analysts forecast that Sysmex Corporation ADR will post 0.42 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.